Loading
Elite Pharmaceuticals Inc Stock: price and insider trades · United States
1 insider bought €31k of shares over the last 90 days, the latest by Dash Barry H, filed 19 Oct 2026.
Elite Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Elite Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 24 October 2025 and 24 October 2026, 2 insiders published 3 filings.
Only purchases show up on the open market, 2 purchases in all worth €31k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive. Biggest ticket of the year: €23k, bought by Dash Barry H and made public on 19 October 2026 (0.0096% of market cap).
The clock since the last published purchase (19 October 2026) now reads 5 days. Typically, a trade is published a median of 10 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 282 companies) published 8 filings over the same period, against 3 filings here. The full history, which starts in 2006, counts 49 purchases against 138 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 March 2026), the company reported revenue of 148.9 m USD and net income of 44.9 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
324
Thresholds
n/a
Buy Volume
€427,161
49 ops. · all time
Sell Volume
€5M
138 ops. · all time
Who traded when
BuySaleBarry H. Dash2 buys
Douglas Plassche2 sales
Elite Pharmaceuticals Inc /NV/1 sale
Kirko Kirkov1 buy
Since the insiders bought
- -3.8%Entry US$0.26 · Close 22 Oct 2026 US$0.25
- -29.1%Entry US$0.55 · Close at T+365 US$0.39
- -12.5%Entry US$0.32 · Close at T+365 US$0.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 214 of 26,290 companies
88.3
score / 100
Value88
Quality89
FCF yld8.5%
Earn yld17%
EV/EBITDA4.6x
ROE74%
Gross mgn50%
Net mgn30%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$0.25
Analyst consensus
Income statement
RevenueUS$148.9M
Gross profitUS$75M50% margin
EBITDAUS$59.2M40% margin
Net incomeUS$44.9M40.2% margin
Valuation
PER (trailing)6.3x
P/Book2.6x
Beta0.33
Balance sheet & cash
Market capUS$269.3M
Total debtUS$5.8M
Free Cash FlowUS$22.8M
Debt / Equity5%
Profitability & ownership
ROE74.3%
ROA17.8%
% insiders22.4%
% institutions0.0%
Last declaration on 19 October 2026
Declarations324 total
100,000 shares@ US$0.25980.0096% mcap26.9% of flowCommon StockSEC:0001493152-26-047486:0
Canonical exit: 7 Jan 2027 (T+90)
30,000 shares@ US$0.2870.0031% mcap4.2% of flowCommon StockSEC:0001324222-26-000001:0
Canonical exit: 17 Nov 2026 (T+90)
2,500,000 shares@ US$0.036.3% of flowStock Options (right to buy)SEC:0001493152-26-002062:0
800,000 shares@ US$0.62441.9% of flowcommon stockSEC:0001493152-25-016979:0
2,500,000 shares@ US$0.0322.2% of flowCommon StockSEC:0001493152-25-012347:1
500,000 shares@ US$0.5243100.0% of flowCommon StockSEC:0001493152-25-012347:0
16,366 shares@ US$0.589100.0% of flowCommon StockSEC:0001946043-25-000002:0
Canonical exit: 8 Oct 2025 (T+90)
200,000 shares@ US$0.5799.7% of flowStock Options (right to buy)SEC:0001641172-25-018593:0
2,500,000 shares@ US$0.036.3% of flowStock Options (right to buy)SEC:0001641172-25-018199:0
333,932 shares@ US$0.5112.3% of flowCommon StockSEC:0001493152-24-042726:1
800,000 shares@ US$0.4935.8% of flowCommon StockSEC:0001493152-24-042726:0
49,534,368 shares0Common StockSEC:0001493152-24-012832:0
2,223,147 shares@ US$0.069100.0% of flowCommon StockSEC:0001583742-23-000001:0
547,657 shares@ US$0.036529.2% of flowCommon StockSEC:0001324222-23-000001:0
547,657 shares@ US$0.036533.1% of flowCommon StockSEC:0001324222-23-000003:0
547,657 shares@ US$0.036533.1% of flowCommon StockSEC:0001324222-23-000002:0
459,536 shares@ US$0.043532.1% of flowCommon StockSEC:0001324222-22-000001:0
459,536 shares@ US$0.043536.4% of flowCommon StockSEC:0001324222-22-000002:0
459,536 shares@ US$0.043536.4% of flowCommon StockSEC:0001324222-22-000003:0
295,570 shares@ US$0.067730.5% of flowCommon StockSEC:0001324222-21-000002:0
295,570 shares@ US$0.067730.5% of flowCommon StockSEC:0001324222-21-000003:0
295,570 shares@ US$0.067726.9% of flowCommon StockSEC:0001324222-21-000001:0
158,017,321 shares0Common StockSEC:0001583742-20-000002:0
71,739 shares@ US$0.08760.5% of flowCommon StockSEC:0001324222-20-000005:0
516,781 shares@ US$0.087140.7% of flowCommon StockSEC:0001324222-20-000004:0
25 of 324 declarations
About Elite Pharmaceuticals Inc
Elite Pharmaceuticals, Inc. (ELTP) is a United States pharmaceutical company whose shares are traded in the U.S. on a NASDAQ/NYSE-type market. The company is based in Northvale, New Jersey, and was incorporated in 1997 under Delaware law. Elite has built its business around niche generic pharmaceuticals, while historically also pursuing branded development programs under NDA pathways. In its recent SEC disclosures, the company states that it focuses on manufacturing approved ANDA-based generic products, developing additional generic candidates, and advancing selected pipeline products through partnerships, licensing, co-development, and related commercialization arrangements. Elite also disclosed that it has paused further development of NDA programs, signaling a more focused capital allocation strategy and a stronger emphasis on near- to medium-term commercial opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001053369/000149315226007104/form10-q.htm?utm_source=openai))
From a competitive standpoint, Elite is best described as a specialty pharmaceutical player rather than a large integrated drugmaker. Its edge lies in operating in narrower product markets where formulation complexity, regulatory know-how, and timing of launches can matter as much as scale. The company’s model combines its own-label sales with licensing and collaboration structures, which can broaden reach while helping spread development risk. Its core commercial footprint is the United States, which is also the key regulatory market for its portfolio. That domestic focus simplifies the narrative for investors but also means the company remains highly exposed to U.S. FDA approvals, pricing dynamics, and generic competition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017134/form10-k.htm?utm_source=openai))
Read moreShow less
Recent operating news has been constructive. For the fiscal year ended March 31, 2025, Elite reported revenue of $84.0 million, up about 48% year over year, and operating profit of $19.6 million, up about 81% versus the prior year. Management attributed the improvement mainly to sales of lisdexamfetamine products launched during fiscal 2025 and to strong growth in Elite label product lines introduced in the previous fiscal year. For investors, this indicates a business that is increasingly benefiting from product launches and commercialization momentum rather than relying solely on long-duration development milestones. In short, ELTP remains a U.S.-listed small-cap pharma name with a concentrated generic-specialty profile, improving operating leverage, and a business model tied closely to execution in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/ex99-1.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
